Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine Extended Release for Aggression in Prader-Willi Syndrome
NCT04066088Phase 4Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Dec 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Placebo Arm with GXR Arm (2 arms). Primary endpoint: Clinical Global Impression - Improvement at 19 weeks. Planned start Dec 2019; status: withdrawn.
02
Drugs
guanfacine
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT04066088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066088.